NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD
1.62
-0.01 (-0.61%)
The current stock price of GLMD is 1.62 USD. In the past month the price decreased by -6.9%. In the past year, price decreased by -65.53%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.82 | 319.07B | ||
AMGN | AMGEN INC | 14.12 | 150.46B | ||
GILD | GILEAD SCIENCES INC | 13.71 | 132.33B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
NTRA | NATERA INC | N/A | 20.88B | ||
BIIB | BIOGEN INC | 7.26 | 17.49B |
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 6
Company Website: https://www.galmedpharma.com
Investor Relations: http://galmedpharma.investorroom.com/
Phone: 97236938448
The current stock price of GLMD is 1.62 USD. The price decreased by -0.61% in the last trading session.
The exchange symbol of GALMED PHARMACEUTICALS LTD is GLMD and it is listed on the Nasdaq exchange.
GLMD stock is listed on the Nasdaq exchange.
7 analysts have analysed GLMD and the average price target is 12.24 USD. This implies a price increase of 655.56% is expected in the next year compared to the current price of 1.62. Check the GALMED PHARMACEUTICALS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 3.66M USD. This makes GLMD a Nano Cap stock.
GALMED PHARMACEUTICALS LTD (GLMD) currently has 6 employees.
GALMED PHARMACEUTICALS LTD (GLMD) has a resistance level at 1.63. Check the full technical report for a detailed analysis of GLMD support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLMD does not pay a dividend.
GALMED PHARMACEUTICALS LTD (GLMD) will report earnings on 2025-05-07.
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-39.12).
The outstanding short interest for GALMED PHARMACEUTICALS LTD (GLMD) is 0.33% of its float. Check the ownership tab for more information on the GLMD short interest.
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. The financial health of GLMD is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -39.12. The EPS increased by 68.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.63% | ||
ROE | -46.04% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to GLMD. The Buy consensus is the average rating of analysts ratings from 7 analysts.